Skip to main content

Advertisement

SpringerLink
Log in

Clinical significance of Cox-2, Survivin and Bcl-2 expression in hepatocellular carcinoma (HCC)

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Cox-2, Survivin and Bcl-2 are frequently overexpressed in numerous types of cancers. They are known to be the important regulators of apoptosis. This study was designed to investigate the correlation between the clinical characteristics and the expression of Cox-2, Survivin and Bcl-2 in hepatocellular carcinoma. A total of 63 postoperative hepatocellular carcinoma (HCC) samples, 10 adjacent non-tumor samples and 10 normal liver samples were immunochemically detected for the expression of Cox-2, Survivin and Bcl-2. A median follow-up of 4 years for the 63 HCC patients was conducted. Univariate tests and multivariate Cox regression were performed for statistical analysis. The Kaplan–Meier method was used to analyze the survival. Positive expression of Cox-2 (84.3%) and Survivin (77.8%) was detected significantly more frequently in the HCC samples than in the normal liver tissues (30% and 0, respectively). Bcl-2 was highly expressed in the adjacent non-tumor tissue. Cox-2 was positively correlative to Survivin. Survivin and Bcl-2 were significantly associated with the pathological grade of HCC (P < 0.05). Expression of both Cox-2 and Survivin was significantly associated with the poor overall survival (OS) (P = 0.0141, P = 0.0039). Furthermore, multivariate analysis confirmed the independent prognostic value of Survivin expression, along with tumor size and hepatic function. Cox-2 and Survivin were highly expressed in the HCC tissue. Survivin and Bcl-2 were significantly associated with the pathological grade of HCC. The expression of Survivin was an independent prognostic factor for HCC after a hepatectomy. Treatment that inhibits Survivin may be a promising targeted approach in HCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Bruix J, Sherman M, Llovet J, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the study of the liver. J Hepatol. 2001;35(3):421–30.

    Article  PubMed  CAS  Google Scholar 

  2. Parkin DM, Bray F, Ferlay J, et al. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001;94(2):153–6.

    Article  PubMed  CAS  Google Scholar 

  3. Thomas MB, Zhu AX. Hepatocellular carcinoma: the need for progress. J Clin Oncol. 2005;23:2892–9.

    Article  PubMed  Google Scholar 

  4. Kelley RK, Alan P. Venook. Sorafenib in hepatocellular carcinoma: separating the hype from the hope. J Clin Oncol. 2008;26:5845–8.

    Article  PubMed  Google Scholar 

  5. Zhu AX, Sahani DV, Duda DG, et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol. 2009;27:3027–35.

    Article  PubMed  CAS  Google Scholar 

  6. Koki AT, Masferer JL. Celecoxib: a specific Cox-2 inhibitor with anticancer properties. Cancer Control. 2002;9(2Suppl):28–35.

    PubMed  Google Scholar 

  7. Santini D, Vincenzi B, Tonini G et al. Cyclooxygenase -2 overexpression is associated with a poor outcome in resected ampullary cancer patients. Clin Cancer Res. 2005;11(10):3784–9.

    Google Scholar 

  8. Shi H, Xu JM, Hu NZ, Xie HJ. Prognostic significance of expression of cyclooxygenase-2 and vascular endothelial growth factor in human gastric carcinoma. World J Gastroenterol. 2003;9:1421–6.

    PubMed  CAS  Google Scholar 

  9. Khuri FR, Wu H, Lee JJ, et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res. 2001;7:861–7.

    PubMed  CAS  Google Scholar 

  10. Ferrandina G, Ranelletti FO, Legge F, et al. Prognostic role of the ratio between cyclooxygenase-2 in tumor and stroma compartments in cervical cancer. Clin Cancer Res. 2004;10:3117–23.

    Article  PubMed  CAS  Google Scholar 

  11. Raspollini MR, Amunni G, Villanucci A, et al. Expression of inducible nitric oxide synthase and cyclooxygenase-2 in ovarian cancer: correlation with clinical outcome. Gynecol Oncol. 2004;92:806–12.

    Article  PubMed  CAS  Google Scholar 

  12. Kawasaki H, Toyoda M, Shinohara H, et al. Expression of Survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer. 2001;91:2026–32.

    Article  PubMed  CAS  Google Scholar 

  13. Salz W, Eisenberg D, Plescia J, et al. A survivin gene signature predicts aggressive tumor behavior. Cancer Res. 2005;65:3531–4.

    Article  PubMed  CAS  Google Scholar 

  14. Sui L, Dong Y, Ohno M, et al. Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors. Int J Oncol. 2002;21:315–20.

    PubMed  CAS  Google Scholar 

  15. Caldas H, Jaynes FO, Boyer MW, et al. Survivin and granzyme B-induced apoptosis, a novel anticancer therapy. Mol Cancer Ther. 2006;5:693–703.

    Article  PubMed  CAS  Google Scholar 

  16. Ryan BM, Konecny GE, Kahlert S, et al. Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. Ann Oncol. 2006;17:597–604.

    Article  PubMed  CAS  Google Scholar 

  17. Reed JC, Miyashita T, Takayama S, et al. Bcl-2 proteins: relators of cell death in the pathogenesis of cancer and resistance to therapy. J Cell Biochem. 1996;60(1):23–32.

    Article  PubMed  CAS  Google Scholar 

  18. Martínez-Arribas F, Alvarez T, Del Val G, et al. Bcl-2 expression in breast cancer: a comparative study at the mRNA and protein level. Anticancer Res. 2007;27:219–22.

    PubMed  Google Scholar 

  19. Leahy DT, Mulcahy HE, O‘Donoghue DP, et al. Bcl-2 protein expression is associated with better prognosis in colorectal cancer. Histopathology. 1999;35(4):360–7.

    Article  PubMed  CAS  Google Scholar 

  20. Athanassiadou P, Grapsa D, Athanassiades P, et al. The prognostic significance of Cox-2 and survivin expression in ovarian cancer. Pathol Res Pract. 2008;204:241–9.

    Article  PubMed  Google Scholar 

  21. Barnes N, Haywood P, Flint P, et al. Survivin expression in in situ and invasive breast cancer relates to Cox-2 expression and DCIS recurrence. Br J Cancer. 2006;94:253–8.

    Article  PubMed  CAS  Google Scholar 

  22. Krysan K, Merchant FH, Zhu L, et al. Cox-2-dependent stabilization of Survivin in non-small cell lung cancer. FASEB J. 2004;18:206–8.

    PubMed  CAS  Google Scholar 

  23. Lu CD, AltieriD C, Tanigawa N, et al. Expression of a novel Antiapoptosis gene, Survivin, correlated with tumor cell apoptosis and p53 accumulationin gastric carcinomas. Cancer Res. 1998;58(9):1808–12.

    PubMed  CAS  Google Scholar 

  24. Wang M, Wang B, Wang X. A novel antiapoptosis gene, survivin, Bcl-2, p53 expression in cervical carcinomas. Zhonghua Fu Chan KeZaZhi. 2001;36(9):54–68.

    CAS  Google Scholar 

  25. Sheng HM, Shao J, Morrow JD, et al. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res. 1998;58(2):362–6.

    PubMed  CAS  Google Scholar 

  26. Liu XH, Yao S, Kirschenbaum A, et al. NS398, a selective cyclooxy genase-2 inhibitor, induces apoptosis and down-regulates Bcl-2 expression in LNCaP cells. Cancer Res. 1998;58(19):4245–9.

    PubMed  CAS  Google Scholar 

  27. Cheng J, Imanishi H, Iijima H, et al. Expression of cyclooxygenase- 2 and cytosoli phospholipase A2 in the liver tissue of patients with chroni-chepatitis and liver cirrhosis. Hepatol Res. 2002;23(3):185–95.

    Article  PubMed  CAS  Google Scholar 

  28. Koga H, Sakisaka S, Ohishi M, et al. Expression of cyclooxygenase-2 in human hepatocellular carcinoma : relevance to tumor dedifferentiation. Hepatology. 1999;29:688–96.

    Article  PubMed  CAS  Google Scholar 

  29. Bae SH, Jung ES, Park YM, et al. Expression of cyclooxigenase-2 (Cox-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a Cox-2 inhibitor, NS-398. Clin Cancer Res. 2001;7:1410–8.

    PubMed  CAS  Google Scholar 

  30. Kondo M, Yamamoto H, Nagano H, et al. Increased expression of Cox-2 in nontumor liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma. Clin Cancer Res. 1999;5:4005–12.

    PubMed  CAS  Google Scholar 

  31. Tang TC, Poon RT, Lau CP, et al. Tumor cyclooxygenase-2 levels correlate with tumor invasiveness in human hepatocellular carcinoma. World J Gastroenterol. 2005;11(13):1896–902.

    PubMed  CAS  Google Scholar 

  32. Schmitz KJ, Wohlschlaeger J, Lang H, et al. Cyclo-oxygenase-2 overexpression is a feature of early and well-differentiated hepatocellular carcinoma with a favourable prognosis. J Clin Pathol. 2009;62:690–3.

    Article  PubMed  CAS  Google Scholar 

  33. Gianani R, Jarboe E, Orlicky D, et al. Expression of Survivin in normal, hyperplastic, and neoplastic colonic mucosa. Hum Pathol. 2001;32(1):119–25.

    Article  PubMed  CAS  Google Scholar 

  34. Grossman D, McNiff JM, Li F, et al. Expression of the apoptosis inhibitor, Survivin, in non melanoma skin cancer and gene targeting in a keratinocyte cell line. Lab Invest. 1999;79(9):1121–6.

    PubMed  CAS  Google Scholar 

  35. Weikert S, Christoph F, Schrader M, et al. Quantitative analysis of Survivin mRNA expression in urine and tumor tissue of bladder cancer patients and its potential relevance for disease detection and prognosis. Int J Cancer. 2005;116(1):100.

    Article  PubMed  CAS  Google Scholar 

  36. Osman HG, Gabr OM, Lotfy S, et al. Serum levels of Bcl-2 and cellular oxidative stress in patients with viral hepatitis. Indian J Med Microbiol. 2007;25:323–9.

    Article  PubMed  CAS  Google Scholar 

  37. Wu T, Leng J, Han C, et al. The cyclooxygenase inhibitor celecoxib block sphosphory lationos Akt and induces apoptosis in human cholangiocarcinoma cells. Mol Cancer Ther. 2004;3(3):299–307.

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors would like to thank all their colleagues who participated in this study. Special thanks to Dr WeiWang, Dr WeiJiang (West China 2nd University Hospital, Si Chuan University).

Competing interests

The author(s) declare that they have no competing interests.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Cancer Center of West China Hospital, Sichuan University, Chengdu, China

    Yu Yang, Jiang Zhu, Hongfeng Gou, Dan Cao, Ming Jiang & Mei Hou

  2. Department of Thoracic Oncology, Cancer Center of West China Hospital, Sichuan University, Chengdu, China

    Jiang Zhu & Mei Hou

Authors
  1. Yu Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jiang Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hongfeng Gou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dan Cao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ming Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mei Hou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mei Hou.

Additional information

Yu Yang and Jiang Zhu equally contributed to this work. Yu Yang and Jiang Zhu designed this study, analyzed the data and drafted the manuscript. Yu Yang, Hong Feng Gou and Dan Cao enrolled and followed up patients in the clinical protocol. Ming Jiang did immunohistochemistry assay. Mei Hou was in charge of the clinical protocol. All authors read and approved the final manuscript.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yang, Y., Zhu, J., Gou, H. et al. Clinical significance of Cox-2, Survivin and Bcl-2 expression in hepatocellular carcinoma (HCC). Med Oncol 28, 796–803 (2011). https://doi.org/10.1007/s12032-010-9519-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-010-9519-y

Keywords

Search

Navigation